From Nobel to next-gen: Sweden’s quiet life sciences ascent
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Bavarian Nordic’s shareholders and board in standoff amid takeover offer
Bavarian Nordic’s board of directors has urged shareholders to accept a sweetened takeover offer as the potential sale of the…
-
Kailera nets $600m to power Phase III launch of obesity drug
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another financing…
-
BIOSECURE returns to US pharma agenda with 2.0 update
After a year in the shadows, the controversial BIOSECURE Act could make a return following an endorsement of a revised…
-
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the…
-
Flu vaccine uptake increases 28% in England
The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both…
-
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
Novo Nordisk has agreed to buy Akero Therapeutics in a deal rising to a potential $5.2bn, as the Danish drugmaker…
-
Amazon Pharmacy kiosks to provide prescription medications in minutes
Amazon Pharmacy is set to launch kiosks filled with prescription medicines that will allow patients to pick up prescriptions immediately…
-
China accounts for one-fifth of global drugs in development
China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in…
-
MapLight’s $251m IPO sees schizophrenia drug developers on top
MapLight Therapeutics aims to raise around $251m via an initial public offering (IPO), a figure that would propel the biotech…